Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 11OTHER 6NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 9Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive 1Endometrial Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Brain Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Carboplatin 43Paclitaxel 33Specimen Handling 15Taxes 14Cyclophosphamide 14Magnetic Resonance Spectroscopy 12Gemcitabine 12Biopsy 12Bevacizumab 12aldesleukin 11Immunoglobulin G 11Disulfides 11veliparib 9Topotecan 9Doxorubicin 9Cisplatin 9Docetaxel 8fludarabine 7olaparib 6liposomal doxorubicin 6Oxaliplatin 6Chemotherapy, Adjuvant 5talazoparib 4sargramostim 4pembrolizumab 4cediranib 4Nivolumab 4Fluorouracil 4Drug Therapy 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ovarian Neoplasms × Fulvestrant × Clear all
NCT05564377 2026-06-12

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡